Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Cabaletta Bio presented clinical data from the first four patients treated with rese-cel in a preconditioning-free setting, showing 50% of patients maintained drug-free responses for 6 months. The company also shared initial manufacturing and translational data from the first two patients treated with rese-cel using the automated Cell Shuttle platform, demonstrating process consistency and similar clinical outcomes.
Key figures
- Drug Name
- rese-cel (resecabtagene autoleucel)
- Phase Of Trial
- Phase 3
- Response rate
- 50%
- Follow up period
- 6 months
- Patients treated
- 4
- Manufacturing patients
- 2
- Manufacturing follow up period
- 4 weeks
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.